Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by Laine1on Jul 28, 2009 8:26am
326 Views
Post# 16170992

RE: Beware Of Hype Thou Even Big Pharma Can Be Foo

RE: Beware Of Hype Thou Even Big Pharma Can Be FooI have to agree...I have not been impressed with the way this company has executed release of news...they have been quite selective with what they think is important for investors to know instead of strategic telling the entire development story. Why did they release news of patent issuance in India without first indicating intent to proceed with clinical trials in India? The website is unimpressive and does very little to create investor confidence. I agree - SSS needs to focus on what they know, and resist from throwing our random information that is not part of the primary NTX 265 stroke program.

Do I think there is the potential for upside here ? Definitely. I like this stock, and will continue to invest - but I am disappointed in the performance.
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse